By MIKE HOLIFIELD | October 31, 2013“Police! Open up! We know you have a plant inside!”
A recent discussion with Dr. Carl Hart for the upcoming documentary “Blowing Smoke”.
According to the Federal Register, the Drug Enforcement Administration is attempting to schedule CBD and CBN as a Schedule 1 controlled substances under the Controlled Substances Act.
Congress is unaware of this change, and uniformed as to what CBD is.
Here is an excerpt from the proposed changes:
CBD Extract Reschedule Summary
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308 [Docket No. DEA–342P] RIN 1117–AB33
Establishment of a New Drug Code for Marihuana Extract
AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Notice of proposed rule-making.
SUMMARY: The Drug Enforcement Administration (DEA) is proposing to create a new Administration Controlled Substances Code Number (‘‘Code Number’’ or ‘‘drug code’’) under 21 CFR 1308.11 for ‘‘Marihuana Extract.’’ This Code Number will allow DEA and DEA- registered entities to track quantities of this material separately from quantities of marihuana.
This in turn will aid in complying with relevant treaty provisions.
Under international drug control treaties (administered by the United Nations), some differences exist between the regulatory controls pertaining to marihuana extract versus those for marihuana and tetrahydrocannabinols.
DEA has established separate Code Numbers for marihuana and for tetrahydrocannabinols, but not for marihuana extract.
To better track these materials and better comply with treaty provisions, DEA is proposing to create a separate Code Number for marihuana extract under 21 CFR 1308.11(d)(36): ‘‘Marihuana Extract meaning extracts that have been derived from any plant of the genus cannabis and which contain cannabinols and cannabidiols.’’
Such extracts of marihuana would continue to be treated as schedule I controlled substances. (Emphasis added)
In 1973 President Richard Nixon created the Drug Enforcement Administration (DEA) claiming there was a junkie explosion with eight times as many heroin addicts as two years earlier (a lie), and that drugs were “decimating a generation of Americans.”
At the time, far more Americans were dying from choking on food or falling down stairs. (Baum, pp. 12, 28)
In reality, Nixon saw the DEA as a jurisdiction-free police force that would indirectly target blacks saying, “You have to face the fact that the whole problem is really the blacks. The key is to devise a system that recognizes this all while not appearing to.” (Baum, p. 13)
An assistant to Egil Krogh, a member of Nixon’s administration imprisoned in the Watergate scandal, explained, “If we hyped the drug problem into a national crisis, we knew that Congress would give us anything we asked for.” (Epstein, p. 140)
While president, Nixon would get drunk and pop pills from his private stash.
Nixon’s statistical deceit regarding heroin addict numbers is explained in Agency of Fear: Opiates and Political Power in America. (pp. 174-177)
When Nixon later wanted to show his War on Drugs was working the addict population was magically sliced by 25%.
The Nixon quotes are from Dan Baum’s Smoke and Mirrors: The War on Drugs and the Politics of Failure. Baum took the “blacks” quote from the diary of Nixon’s Chief of Staff, H.R. Haldeman.
Another quote in Haldeman’s diary was that Nixon wanted to know “why all the Jews seem to be the ones that are for liberalizing the regulations on marijuana.” (p. 54)
Nixon’s generous use of drugs – prescribed and not prescribed (Dilantin) – and alcohol is detailed in Anthony Summers’The Arrogance of Power: The Secret World of Richard Nixon.
1. Robert Arthur, You Will Die: The Burden of Modern Taboos (2008).
2. Dan Baum, Smoke and Mirrors: The War on Drugs and the Politics of Failure (1996).
3. Edward Jay Epstein, Agency of Fear: Opiates and Political Power in America (1977).
4. Anthony Summers, The Arrogance of Power: The Secret World of Richard Nixon (2000).
Sam Sabzehzar is one of the Co-founders of Medical Marijuana 411. With a foundation of investigative and transactional research on botanicals delivered to the body’s endocannabinoid system, Mr. Sabzehzar has developed unparalleled expertise in the cannabis industry. Throughout, he has established rich relationships with diverse individuals and organizations including nonprofits focused on advocacy, public policy, and science.